Replimune Group (REPL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.79
- Surprise
- —
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Replimune Group Q2 EPS $(0.54) Beats $(0.77) Estimate — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates REPL Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Pipeline: RPx platform
- Concentration risk — Supplier: BMS nivolumab supply
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.05
- Price target
- $16.96
- Stop
- $12.14
- Upside to target
- +30.0%
- Reward-to-risk
- 2.0:1
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
REPL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.23B
- P/E (fwd)
- -7.2
- 52-week range
- $1.50–$16.33
- Off 52-week high
- 20.1%
- RSI (14)
- 49
- Volume vs avg
- 2.13×
- Score today
- 5.4/10